LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday ...

CASE DETAILS: According to the complaint ... "a 68-week efficacy and safety trial investigating subcutaneous CagriSema." The trial showed that patients treated with CagriSema exhibited weight ...

CASE DETAILS: According to the complaint ... "a 68-week efficacy and safety trial investigating subcutaneous CagriSema." The trial showed that patients treated with CagriSema exhibited weight ...

CASE DETAILS: According to the complaint ... "a 68-week efficacy and safety trial investigating subcutaneous CagriSema." The trial showed that patients treated with CagriSema exhibited weight ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot missed ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December.

All three have featured fashionable yet functional styles from Bandolier, the brand behind celebrities’ go-to crossbody phone cases. Like all of the brand’s gadgets, the handy designs feature ...

The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S . Shareholders who purchased shares of NVO ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

By now, you’ve probably seen the term “RFID-blocking” advertised with wallets and phone cases alike — but what does it really mean? RFID, or Radio Frequency Identification, is the mechanism used to ...

CASE ALLEGATIONS: Novo Nordisk ... information pertaining to Novo Nordisk’s projected successful outcome of Novo Nordisk’s phase 3 CagriSema study on obesity, named “REDEFINE-1,” while avoiding ...